IRIS
SCALISE, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.962
EU - Europa 2.707
AS - Asia 1.326
AF - Africa 84
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 9.091
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.946
UA - Ucraina 779
SG - Singapore 494
TR - Turchia 410
IE - Irlanda 409
SE - Svezia 329
DE - Germania 322
DK - Danimarca 292
IT - Italia 204
CN - Cina 198
FI - Finlandia 166
KR - Corea 160
FR - Francia 122
CI - Costa d'Avorio 69
GB - Regno Unito 44
IR - Iran 27
HK - Hong Kong 26
CA - Canada 16
MA - Marocco 13
BE - Belgio 11
IN - India 8
NL - Olanda 7
RO - Romania 6
CL - Cile 5
BG - Bulgaria 4
EU - Europa 3
AR - Argentina 2
CM - Camerun 2
CY - Cipro 2
ES - Italia 2
PL - Polonia 2
A1 - Anonimo 1
AL - Albania 1
EE - Estonia 1
HR - Croazia 1
IS - Islanda 1
LV - Lettonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RU - Federazione Russa 1
VN - Vietnam 1
Totale 9.091
Salva come PNG Salva come JPEG
Città #
Jacksonville 784
Chandler 506
Fairfield 491
Dublin 409
Boardman 370
Wilmington 287
Singapore 241
Ashburn 240
Woodbridge 228
Houston 198
New York 185
Cambridge 168
Seattle 165
Lawrence 157
Princeton 157
San Mateo 156
Ann Arbor 140
Des Moines 82
Abidjan 69
Turin 60
San Diego 52
Beijing 24
Hong Kong 24
Izmir 23
Shanghai 21
Wuhan 15
Norwalk 14
Guangzhou 13
Falls Church 12
Redmond 12
Brussels 11
Helsinki 11
Los Angeles 11
Kilburn 10
Ottawa 10
London 9
Centro 8
Buffalo 7
Dallas 6
Jiaxing 6
Wuxi 6
Seoul 5
Washington 5
Amsterdam 4
Pesaro 4
Venice 4
Andover 3
Campobasso 3
Chizhou 3
Cingoli 3
Delhi 3
Macerata 3
Milan 3
North Bergen 3
Palermo 3
San Jose 3
Toronto 3
Acton 2
Arco 2
Buenos Aires 2
Cava De' Tirreni 2
Central 2
Dalian 2
Hangzhou 2
Hounslow 2
Marche 2
Nicosia 2
Olgiate Comasco 2
Serra 2
Shenzhen 2
Simi Valley 2
Tehran 2
Tiantai Chengguanzhen 2
Yiwu 2
Appignano 1
Auburn Hills 1
Auckland 1
Barcelona 1
Belvedere Spinello 1
Bologna 1
Chiswick 1
Clifton 1
Cologno Monzese 1
East Los Angeles 1
Fayetteville 1
Ferrara 1
Florence 1
Fort Worth 1
Hanover 1
Hull 1
Kunshan 1
La Canada Flintridge 1
Las Vegas 1
Lianyun 1
Lisbon 1
Longyan 1
Marseille 1
Montesilvano 1
Montréal 1
Moscow 1
Totale 5.513
Salva come PNG Salva come JPEG
Nome #
Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections 204
Antimicrobial Resistance: A Challenge for the Future 162
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides 139
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. 131
Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. 123
RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 118
Anticryptosporidial activity of paromomycin. 110
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock 92
Epidemiology and microbiology of surgical wound infections. 83
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 82
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 82
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 81
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 81
In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. 79
In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 78
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 78
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 76
Amphibian Peptides Prevent Endotoxemia and Bacterial Translocation in Bile Duct-Ligated Rats 74
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 74
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 73
Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock 73
In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 73
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. 73
RNAIII-Inhibiting Peptide-Loaded Polymethylmethacrylate Prevents In Vivo Staphylococcus aureus Biofilm Formation 72
In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. 71
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. 71
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. 71
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock 71
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock 71
In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. 70
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 70
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 70
Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. 70
In- vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii. 70
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 69
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 69
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 69
In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus faecalis and interactions with clinically used antibiotics. 68
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 68
Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide 67
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 67
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 66
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 66
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. 66
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. 65
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 64
Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. 64
Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide 63
In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. 63
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 63
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. 63
Effect of mono-dose intraperitoneal cecropins in experimental septic shock 63
Treatment of Staphylococcus aureus Biofilm infection by the quorum sensing inhibitor RIP 62
In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. 62
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 62
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 62
[Vascular graft infection by Staphylococcus epidermidis: efficacy of various perioperative prophylaxis protocols in an animal model]. 62
LL-37 protects rats against lethal gram-negative sepsis. 61
In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 61
In vitro activities of tachyplesin III against Pseudomonas aeruginosa. 61
Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. 61
In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. 61
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 61
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 60
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 60
Potential therapeutic role of cationic peptides in three experimental models of septic shock 58
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 58
The bovine antimicrobial peptide BMAP-28 reduces lethality due to bacterial cell wall components in mouse models of staphylococcal sepsis 57
In-Vitro Activity of Histatins Derivative P-113 Alone and in Combination with Antimicrobial Agents Against Multidrug-Resistant Pathogens Responsible of Pneumonia in Immunocompromised Patients. 57
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to multiresistant Pseudomonas aeruginosa strain 56
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 56
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 56
Polycationic peptides as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection 55
Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? 54
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. 54
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. 54
In Vitro Activity of Aurein 1.2 Alone and in Combination with Antibiotics against Gram-positive Nosocomial Cocci 54
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 54
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. 54
Potential therapeutic role of histatins derivative P-113D in experimental rat models of Pseudomonas sepsis 53
Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. 53
[Prevalence of Toxocara spp in public playgrounds in a town of Central Italy] 53
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. 53
[Giardiasis: a parasitic disease of continued topicality. Study of prevalence among a selected adult population] 53
Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa. 53
Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. 53
RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. 53
HIV and HBV infection in subjects referred to a dermatological clinic. 53
Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. 52
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 52
The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock 52
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock 52
In-vitro effect of short-term exposure to cathelicidin peptides on Cryptosporidium parvum. 51
In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. 51
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. 51
In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 51
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. 51
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 50
Efficacy of Tachyplesin III, Colistin and Imipenem against Multiresistant Pseudomonas aeruginosa 49
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. 49
Totale 6.860
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.091
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.091
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020602 0 0 0 0 0 3 167 3 160 18 19 232
2020/20212.164 115 250 325 42 242 159 216 147 207 166 195 100
2021/20221.154 88 240 0 51 9 106 45 63 73 194 37 248
2022/20231.684 202 170 135 121 124 180 4 82 487 8 128 43
2023/20241.032 212 18 44 190 200 201 15 7 5 5 25 110
2024/2025894 280 199 177 113 105 20 0 0 0 0 0 0
Totale 9.246